Ki Chang, MD
Internal Medicine · Southaven, MSNPI 1649363656
Payments from drug & device makers
Across 308 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$835
- AbbVie$731
- AstraZeneca$645
- Novo Nordisk$491
- Bayer$475
- Boehringer Ingelheim$334
- plus $2K from 26 others
What the payments were for
- Travel & lodging$2585%
- Food & beverage$5,25795%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 56 | $835 |
| AbbVie(2 entities) | 44 | $731 |
| AstraZeneca | 31 | $645 |
| Novo Nordisk | 28 | $491 |
| Bayer | 24 | $475 |
| Boehringer Ingelheim | 18 | $334 |
| Amgen | 19 | $327 |
| Medtronic | 4 | $292 |
| Kowa Pharmaceuticals America, Inc. | 8 | $185 |
| GSK | 16 | $185 |
| Pfizer | 8 | $125 |
| Phathom Pharmaceuticals, Inc. | 8 | $100 |
| Abbott | 5 | $98 |
| Amarin Pharma, Inc. | 6 | $85 |
| Johnson & Johnson | 4 | $79 |
| Merck | 4 | $71 |
| Dexcom, Inc. | 3 | $66 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $45 |
| Idorsia Pharmaceuticals US Inc | 3 | $45 |
| Antares Pharma, Inc. | 2 | $45 |
| Novartis | 2 | $37 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Shield Therapeutics Inc | 2 | $28 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Pulmonx Corporation | 1 | $24 |
| Edwards Lifesciences | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Boston Scientific | 1 | $16 |
| Assertio Therapeutics, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,515 in reported general payments places this provider in the 85th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 249 | $274,026 |
| OzempicSemaglutide | 138 | $195,820 |
| MounjaroTirzepatide | 59 | $91,039 |
| TrulicityDulaglutide | 25 | $48,063 |
| FarxigaDapagliflozin Propanediol | 60 | $44,727 |
| JanuviaSitagliptin Phosphate | 52 | $37,010 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $28,205 |
| TradjentaLinagliptin | 27 | $27,882 |
| EliquisApixaban | 21 | $25,410 |
| LinzessLinaclotide | 20 | $20,691 |
| XareltoRivaroxaban | 16 | $17,262 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $12,508 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $9,342 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $8,337 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $8,082 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $334 | $314,415287 claims |
| Novo NordiskOzempic | $491 | $195,820138 claims |
| Lilly USA, LLCMounjaro, Trulicity | $835 | $139,10284 claims |
| AstraZenecaFarxiga, Symbicort | $645 | $52,80974 claims |
| MerckJanuvia, Janumet | $71 | $45,34867 claims |
| GSKTrelegy Ellipta | $185 | $28,20536 claims |
| PfizerEliquis | $125 | $25,41021 claims |
| AbbVieLinzess | $731 | $20,69120 claims |
| Johnson & JohnsonXarelto | $79 | $17,26216 claims |
| NovartisEntresto | $37 | $7,27111 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $185 | $6,17816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Southaven
- James HallBrookhaven$4.8M
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
- David PendleyGulfport$336K
- Sarah KerutJackson$319K
- Gabriel HernandezJackson$196K
- Kelly WilkinsonJackson$183K
- Magdy Gorgi-MikhailBiloxi$157K
- Christina BarlowJackson$129K
- Arnold JacksonHattiesburg$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.